Copper Peptide Serum, 1%

Copper Peptides for Hair Growth: Wound-Healing Evidence vs. Hair Growth Evidence

Copper peptides do not have controlled human trial evidence showing they regrow hair. The research trail behind GHK-Cu and its shorter relative AHK-Cu is genuinely strong for skin repair: well established in cell culture and backed by a handful of human facial-skin studies. The hair-specific evidence is a different, much thinner body of work, built on a single 2007 study conducted on isolated follicles and cultured cells outside a living scalp. That distinction, not a marketing claim, is why the Copper Peptide Serum sits on the minoxidil-free shelf as scalp-condition support rather than alongside the range's core regrowth actives.

  • GHK-Cu's strongest evidence is for skin firmness and collagen synthesis, and most of it comes from cell culture or facial-skin studies, not hair or scalp research.
  • The only hair-specific study used follicles and cells removed from the body and grown in organ culture, not a person applying a serum.
  • No independently published controlled trial in living human subjects has shown that a copper peptide regrows hair on an actual scalp.
  • Minoxidil remains the only ingredient in the range with an FDA-approved regrowth indication, and that approval is specific to the vertex in men.

What "evidence" means for a copper peptide serum

GHK-Cu and AHK-Cu are both copper tripeptides, and product pages that sell them often move between the two as if one body of research covers both. It does not. Each claim, whether it is about skin firmness or about hair growth, has its own research trail, and the two trails need to be checked separately before either one gets used to justify the other.

The question worth answering plainly, before anything else, is the one most readers actually have: does this ingredient regrow hair, or does it do something else that still has value for someone treating hair loss? The short answer is the second. Copper peptides have a real, if modest, place in skin care. Whether that translates to the scalp and the hair follicle is exactly what the rest of this article works through.

What the wound-healing and skin-repair literature on GHK-Cu actually shows

GHK-Cu occurs naturally in human blood plasma, and its level falls with age: roughly 200 ng/mL at 20 years old, declining to around 80 ng/mL by 60 (source: Regenerative and Protective Actions of the GHK-Cu Peptide, Pickart & Margolina, 2018). That age-related decline is where the interest in GHK-Cu as a topical ingredient began, on the reasoning that replacing it might restore some of what ageing skin loses.

In cell culture, GHK stimulates fibroblasts to produce more collagen, several glycosaminoglycans and the small proteoglycan decorin, all proteins involved in keeping skin's structural matrix intact. That is a solid, repeatable laboratory finding. In people, the evidence is thinner but real: a 12-week cream study in 71 women with photoaged skin reported increased density and thickness with reduced fine lines and wrinkle depth, and a separate 8-week randomised trial reported reduced wrinkle volume and depth against a control serum. Worth noting plainly: the review article reporting these two studies does not say who sponsored or ran either one, and it states that its own authors declare no conflict of interest, even though those authors do have a broader commercial connection to GHK-Cu as a compound. That is a reason for general caution about the ingredient's literature, not evidence that these particular trials were company-run or company-funded.

This is cosmetic evidence on facial skin. It says something credible about collagen support and fine lines. It says nothing directly about hair follicles or scalp regrowth, and treating the two as the same body of evidence is where most copper-peptide-for-hair content goes wrong. Readers who want the fuller picture of what GHK-Cu is and where its evidence is strongest can read the dedicated explainer on GHK-Cu's chemistry and evidence profile.

The much smaller set of hair-specific studies

The hair-specific research narrows to a single study, published in 2007, that applied AHK-Cu to isolated human hair follicles kept alive in organ culture and to cultured dermal papilla cells (DPCs), the cells at the base of the follicle that help drive hair growth. The result was more follicle elongation and more DPC proliferation, along with a reduction in markers of DPC apoptosis that did not reach statistical significance (source: Pyo et al., Arch Pharm Res, 2007). Those are genuine, measurable effects, and they are the entire basis for "copper peptides grow hair" as a claim.

Why a dish result isn't a head result

Organ culture and in vitro work mean the follicles and cells were removed from the body and kept alive in a lab, not attached to a functioning scalp on a living person. A dish has no blood supply carrying hormones, nutrients and immune signals in and out, no surrounding skin barrier controlling what actually reaches the follicle, and no months-long timeframe over which a real hair cycle plays out. A compound can behave one way isolated in culture and behave differently, or not at all, once it has to penetrate skin, survive the scalp's own chemistry and act on a follicle embedded in living tissue. That gap is exactly why regulators and serious researchers treat an in vitro finding as a reason to run a human trial, not as a substitute for one.

What happened to the 1990s human trials

According to the product's own seller description, a copper-peptide scalp solution was taken into company-run trials for pattern hair loss in the 1990s. It never reached approval, and the full results were never published anywhere a reader can independently check them. That is worth mentioning because it is sometimes cited as if it were supporting evidence, but an unpublished, company-run trial with no available results is not something to weigh either for or against the ingredient. It is simply unverifiable, and it stays that way until someone publishes it.

Put together, the honest position is this: there is a plausible mechanism, a genuine effect in isolated cells and follicles, and no controlled human trial demonstrating that a copper peptide regrows hair on an actual scalp.

Why this sits in the minoxidil-free shelf, not among the five core actives

The FDA-approved label for 5% minoxidil topical solution restricts its indication to regrowth on the top of the scalp, the vertex, in men, and states plainly that it is not intended for a receding hairline or frontal baldness; any regrowth also depends on continued use, since stopping lets hair loss resume (source: DailyMed minoxidil 5% topical solution label). That is a regulatory approval built on controlled human trials, and it is why Minoxidil Topical Solution USP, 5% is the one ingredient in the range with strong regrowth evidence behind it.

Nothing about copper peptides is comparable to that record. What they have is a plausible mechanism and one dish-level result, which is a legitimate starting point for future research but not proof of anything happening on a scalp. That is also why the serum is positioned among the range's minoxidil-free options rather than being marketed alongside minoxidil as an equivalent.

None of this makes the serum worthless. It makes it a different kind of product doing a different job: supporting the condition of the scalp's skin, a role the wound-healing literature does actually back, rather than driving the hair cycle itself. Presenting it that way, rather than borrowing minoxidil's evidence by association, is the more useful thing for a reader trying to decide what to spend money on.

What this means for how you'd actually use it

The scalp is skin, and the rest of a typical hair-loss routine is not gentle on it. Minoxidil solution is carried in alcohol with propylene glycol, and a dermaroller opens the surface on purpose. For someone who has been treating their scalp for months and can feel that the skin has taken the brunt of it, a copper peptide serum's actual job is supporting that skin rather than replacing the treatment doing the regrowth work.

Copper Peptide Serum, 1%, a 30 mL dropper bottle from Quintéa
Copper Peptide Serum, 1% is formulated for the scalp and the face, and is positioned as skin-condition support alongside a regrowth treatment, not as a replacement for one.

Two sequencing details matter if you use it alongside other actives. Copper complexes are destabilised by strong acids and by direct vitamin C, so it helps to keep exfoliating acids and vitamin C to the morning and this serum to the night rather than layering them in the same routine. And if minoxidil goes on the same scalp in the evening, applying the serum first and letting it absorb fully before the minoxidil goes on keeps the two from interfering with each other.

If you are already using a scalp serum such as Redensyl Complex Serum, the more sensible approach is picking one and staying with it for a few months rather than layering both onto the same skin. For anyone weighing options within the minoxidil-free part of the range, the evidence for microneedling is considerably stronger than anything copper peptides currently have, and a broader field guide to hair-growth peptides covers how copper peptides compare to other peptide actives being marketed for the same purpose. If you do decide to try the serum, a realistic before-and-after timeline sets expectations for what changes are actually plausible to notice and by when.

Back to blog